Walleye Capital LLC Grows Stock Holdings in Integra LifeSciences Holdings Corporation $IART

Walleye Capital LLC lifted its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 202.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 218,595 shares of the life sciences company’s stock after acquiring an additional 146,203 shares during the quarter. Walleye Capital LLC’s holdings in Integra LifeSciences were worth $2,059,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Rubric Capital Management LP boosted its holdings in Integra LifeSciences by 1.3% in the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after purchasing an additional 100,000 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Integra LifeSciences by 0.9% in the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after buying an additional 31,931 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after buying an additional 267,134 shares during the period. State Street Corp boosted its stake in shares of Integra LifeSciences by 0.8% in the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after buying an additional 21,717 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY grew its holdings in Integra LifeSciences by 5.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock worth $33,099,000 after acquiring an additional 135,198 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Citigroup reiterated a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Truist Financial upped their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Thursday, June 18th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Finally, BMO Capital Markets began coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price for the company. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Integra LifeSciences presently has a consensus rating of “Reduce” and an average price target of $18.33.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $18.56 on Friday. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. Integra LifeSciences Holdings Corporation has a twelve month low of $8.70 and a twelve month high of $20.26. The business has a 50-day moving average price of $17.28 and a 200 day moving average price of $13.26. The firm has a market cap of $1.44 billion, a PE ratio of -2.87, a P/E/G ratio of 1.30 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. During the same quarter in the prior year, the business posted $0.41 earnings per share. Integra LifeSciences’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.